Observer variation in the application of the pheochromocytoma of the adrenal gland scaled score

American Journal of Surgical Pathology

Volumn 33, Issue 4, 2009, Pages 599-608

  Wu, David ^a   Tischler, Arthur S ^b   Lloyd, Ricardo V ^c   DeLellis, Ronald A ^d   De Krijger, Ronald ^e   Van Nederveen, Francien ^e   Nosé, Vânia ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d BROWN UNIVERSITY   (United States)

^e JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Benign; Malignant; Observer variation; Paraganglioma; PASS; Pheochromocytoma; Pheochromocytoma of the adrenal gland scaled score

Indexed keywords

ADOLESCENT; ADRENAL TUMOR; ADULT; AGED; ARTICLE; CHILD; CLASSIFICATION; FEMALE; HOSPITALIZATION; HUMAN; MALE; METASTASIS; MIDDLE AGED; OBSERVER VARIATION; PHEOCHROMOCYTOMA; PREDICTION AND FORECASTING; PRESCHOOL CHILD; PROGNOSIS; TUMOR RECURRENCE;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OBSERVER VARIATION; PHEOCHROMOCYTOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 63849246546     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318190d12e     Document Type: Article

References (23)

1. August C, August K, Schroeder S, et al. CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod Pathol. 2004;17:1119-1128.
2. Brown HM, Komorowski RA, Wilson SD, et al. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior. Cancer. 1999;86:1583-1589.
3. Castilla-Guerra L, Moreno AM, Fernandez-Moreno MC, et al. Expression and prognostic value of c-erbB-2 oncogene product in human phaeochromocytomas. Histopathology. 1997;31:144-149.
4. Clarke MR, Weyant RJ, Watson CG, et al. Prognostic markers in pheochromocytoma. Hum Pathol. 1998;29:522-526.
5. Cope C, Delbridge L, Philips J, et al. Prognostic significance of nuclear DNA content in phaeochromocytoma. Aust N Z J Surg. 1991; 61:695-698.
6. de Krijger RR, van der Harst E, van der Ham F, et al. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. J Pathol. 1999;188:51-55.
7. de Krijger RR, van Nederveen FH, Korpershoek E, et al. New developments in the detection of the clinical behavior of pheochromocytomas and paragangliomas. Endocr Pathol. 2006;17:137-141.
8. DeLellis RA, Lloyd RV, Heitz PU, et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumour of Endocrine Organs. Lyon: IARC Press; 2004:147-158.
9. Elder EE, Elder G, Larsson C. Pheochromocytoma and functional paraganglioma syndrome: No longer the 10% tumor. J Surg Oncol. 2005;89:193-201.
10. Elder EE, Xu D, Hoog A, et al. KI-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Mod Pathol. 2003;16:246-255.
11. Gao B, Meng F, Bian W, et al. Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas. Urology. 2006;68:282-286.
12. Gimm O. Pheochromocytoma-associated syndromes: Genes, proteins and functions of RET, VHL and SDHx. Fam Cancer. 2005;4:17-23.
13. Gupta D, Shidham V, Holden J, et al. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas. Appl Immunohistochem Mol Morphol. 2000;8:267-274.
14. John H, Ziegler WH, Hauri D, et al. Pheochromocytomas: Can malignant potential be predicted? Urology. 1999;53:679-683.
15. Khorram-Manesh A, Ahlman H, Jansson S, et al. N-cadherin expression in adrenal tumors: Upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma. Endocr Pathol. 2002;13:99-110.
16. Kimura N, Watanabe T, Noshiro T, et al. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: A clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol. 2005;16: 23-32.
17. Kumaki N, Kajiwara H, Kameyama K, et al. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques. Endocr Pathol. 2002; 13:149-156.
18. Linnoila RI, Keiser HR, Steinberg SM, et al. Histopathology of benign versus malignant sympathoadrenal paragangliomas: Clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol. 1990;21:1168-1180.
19. Quiros RM, Kim AW, Maxhimer J, et al. Differential heparanase-1 expression in malignant and benign pheochromocytomas. J Surg Res. 2002;108:44-50.
20. Salmenkivi K, Haglund C, Arola J, et al. Increased expression of tenascin in pheochromocytomas correlates with malignancy. Am J Surg Pathol. 2001;25:1419-1423.
21. Shah MJ, Karelia NH, Patel SM, et al. Flow cytometric DNA analysis for determination of malignant potential in adrenal pheochromocytoma or paraganglioma: An Indian experience. Ann Surg Oncol. 2003;10:426-431.
22. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002;26:551-566.
23. van der Harst E, Bruining HA, Jaap Bonjer H, et al. Proliferative index in phaeochromocytomas: Does it predict the occurrence of metastases? J Pathol. 2000;191:175-180.